Olanzapine Reversed THC-Induced Memory Impairment in Rats, but Haloperidol Did Not
The atypical antipsychotic olanzapine reversed THC's memory-impairing effects in rats by restoring acetylcholine levels in the hippocampus, while the older antipsychotic haloperidol had no effect.
Quick Facts
What This Study Found
Researchers tested whether two different antipsychotic medications could reverse the spatial memory impairment caused by THC in rats using an eight-arm radial maze.
THC (6 mg/kg) impaired spatial memory and decreased acetylcholine (ACh) levels in the dorsal hippocampus, a brain region critical for spatial memory.
Olanzapine (0.1 mg/kg), an atypical antipsychotic, reversed both the memory deficit and the acetylcholine decrease caused by THC. Haloperidol (0.03-0.3 mg/kg), a typical antipsychotic, had no effect on either measure at any dose tested.
The results suggest olanzapine's ability to restore hippocampal acetylcholine release may underlie its reversal of THC-induced cognitive impairment, potentially relevant to treating cannabis-related cognitive effects in patients with psychosis.
Key Numbers
THC dose: 6 mg/kg. Olanzapine 0.1 mg/kg reversed memory deficits and ACh decrease. Haloperidol 0.03-0.3 mg/kg had no effect. THC decreased ACh in dorsal hippocampus.
How They Did This
Rats were tested in an eight-arm radial maze task after receiving THC (6 mg/kg i.p.) with or without olanzapine or haloperidol pretreatment. Extracellular acetylcholine levels in the dorsal hippocampus were measured by in vivo microdialysis.
Why This Research Matters
Many patients with schizophrenia use cannabis, which can worsen their cognitive symptoms. This study suggested that olanzapine (but not haloperidol) may counteract cannabis-induced cognitive impairment, potentially guiding antipsychotic selection for cannabis-using patients.
The Bigger Picture
The distinction between atypical (olanzapine) and typical (haloperidol) antipsychotics in reversing THC effects reflects their different pharmacological profiles. Olanzapine's broader receptor activity, including effects on cholinergic systems, may make it more suitable for cannabis-using patients with psychosis.
What This Study Doesn't Tell Us
Rat spatial memory tasks may not translate to human cognitive function. The THC dose was relatively high. Only one dose of olanzapine was effective. The clinical relevance for humans requires clinical trial confirmation.
Questions This Raises
- ?Do atypical antipsychotics produce better cognitive outcomes in cannabis-using schizophrenia patients?
- ?Could olanzapine-like mechanisms be exploited to treat cannabis-induced cognitive impairment without the metabolic side effects of olanzapine?
Trust & Context
- Key Stat:
- Olanzapine reversed THC memory impairment; haloperidol did not at any dose
- Evidence Grade:
- This is an animal study with clear results but limited clinical translatability. The single effective olanzapine dose and artificial setting limit generalization.
- Study Age:
- Published in 2008. Research on antipsychotic-cannabis interactions has continued, with growing clinical interest in optimizing treatment for cannabis-using psychosis patients.
- Original Title:
- Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.
- Published In:
- Progress in neuro-psychopharmacology & biological psychiatry, 32(2), 499-506 (2008)
- Authors:
- Egashira, Nobuaki(2), Ishigami, Noriko, Mishima, Kenichi(2), Iwasaki, Katsunori, Oishi, Ryozo, Fujiwara, Michihiro
- Database ID:
- RTHC-00311
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does olanzapine work but not haloperidol?
Olanzapine affects a wider range of brain chemical systems than haloperidol, including the cholinergic (acetylcholine) system. Since THC impairs memory partly by reducing acetylcholine, olanzapine's ability to boost acetylcholine may be the key difference.
Does this mean olanzapine protects against cannabis effects in humans?
This was a rat study and cannot directly predict human outcomes. However, it suggests a mechanism that could be tested in clinical studies of antipsychotic choice for cannabis-using patients.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- thc-and-antipsychotics-complicated-relationship
Cite This Study
https://rethinkthc.com/research/RTHC-00311APA
Egashira, Nobuaki; Ishigami, Noriko; Mishima, Kenichi; Iwasaki, Katsunori; Oishi, Ryozo; Fujiwara, Michihiro. (2008). Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.. Progress in neuro-psychopharmacology & biological psychiatry, 32(2), 499-506.
MLA
Egashira, Nobuaki, et al. "Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.." Progress in neuro-psychopharmacology & biological psychiatry, 2008.
RethinkTHC
RethinkTHC Research Database. "Delta9-Tetrahydrocannabinol-induced cognitive deficits are r..." RTHC-00311. Retrieved from https://rethinkthc.com/research/egashira-2008-delta9tetrahydrocannabinolinduced-cognitive-deficits-are
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.